New Key Statistics Module, Z-Score and F-Score
NAS:CARA Key Ratios
Market Cap $ M | 19.09 |
Enterprise Value $ M | -30.04 |
P/E(ttm) | -- |
PE Ratio without NRI | -- |
Forward PE Ratio | -- |
Price/Book | 1.63 |
Price/Sales | 1.70 |
Price/Free Cash Flow | -- |
Price/Owner Earnings | -- |
Payout Ratio % | -- |
Revenue (TTM) $ M | 10.00 |
EPS (TTM) $ | -2.04 |
Beneish M-Score | -5.65 |
10-y EBITDA Growth Rate % | -- |
5-y EBITDA Growth Rate % | -- |
y-y EBITDA Growth Rate % | -- |
EV-to-EBIT | 0.29 |
EV-to-EBITDA | 0.29 |
PEG | -- |
Shares Outstanding M | 54.85 |
Net Margin (%) | -1,010.20 |
Operating Margin % | -941.21 |
Pre-tax Margin (%) | -1,010.20 |
Quick Ratio | 4.48 |
Current Ratio | 4.59 |
ROA % (ttm) | -103.20 |
ROE % (ttm) | -189.52 |
ROIC % (ttm) | -668.56 |
Dividend Yield % | -- |
Altman Z-Score | -17.92 |
CARA Number of Guru Trades
CARA Volume of Guru Trades
Gurus Latest Trades with NAS:CARA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:CARA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Cara Therapeutics Inc Insider Transactions
No Available Data
News about NAS:CARA
Total 0- 1